Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
100%(6 trials)

Phase Distribution

Ph phase_1
1
13%
Ph phase_4
2
25%
Ph phase_3
4
50%

Phase Distribution

1

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 3Large-scale testing
4(57.1%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(1)
Other(1)

Detailed Status

Completed6
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 34 (57.1%)
Phase 42 (28.6%)

Trials by Status

completed675%
withdrawn113%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

NCT05529992
completedphase_4

Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

NCT02574286
completedphase_3

Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease

NCT01614574
completedphase_3

Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease

NCT01842841
completedphase_1

Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease

NCT01685216
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05529992Phase 3

A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Completed
NCT02574286Phase 4

Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

Completed
NCT01614574Phase 3

Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease

Completed
NCT01842841Phase 3

Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease

Completed
NCT01685216Phase 1

Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease

Completed
NCT00553631Phase 3

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

Completed
NCT00954460

Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

Unknown
NCT02528617Phase 4

The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8